Screening of malignant neoplasms in the population of the Republic of Sakha (Yakutia)

This article describes the incidence of malignant neoplasms in the Sakha Republic’s population selected for screening studies and presents an assessment of the results of the Onkopoisk. Sakha (mass screening tests) pilot project. Screening is carried out for six types of malignant neoplasms that are an important problem for regional healthcare. In the course of screening, we carried out 12,826 tests and identified 21 cases of malignant neoplasms and 51 cases of precancerous conditions. The proportion of patients with stage 0-2 malignant processes was 62%.

Preliminary results of Onkopoisk.Sakha demonstrated how it can be useful in screening and early diagnosis of cancer in the Sakha Republic. This screening program using online platforms complements other activities of medical examinations and preventive examinations and is in demand because it meets the requirements of sanitary and epidemiological safety and saves resources.

1. Zlokachestvennye novoobrazovaniya v Rossii v 2007-2019 godu (zabolevaemost' i smertnost') [Malignant Neoplasms in Russia in 2007-2019 (Morbidity and Mortality). MNIOI named. P.A. Gercena – filial FGBU «NMIC radiologii» Minzdrava Rossii [Moscow: P. Herzen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation (In Russ.).] https://old.oncology-association.ru/medstat

2. Cancer Control: Early Detection. WHO Guide for Effective Programs. Geneva: World Health Organization; 2007 (http://apps.who.int/iris/bitstream/10665/43743/1/9241547338_eng.pdf).

3. Cancer statistics, 2020. NCHS, https://doi.org/10.3322/caac.21590

4. Evaluation of screening for cancer. Oxford Textbook of Oncology. Eds. M. Peckham, H. Pinedo, U. Veronesi. Oxford; New York; Tokyo: Oxford University Press, 1995. Vol . 1.P. 185–198.

5. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020. (https://www.who.int/publications/i/item/9789240014107).

6. Oncology Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A systematic Analysis for Global Burden of Diseases Study. Global Burden of Diseases Cancer Collaboration. JAMA Oncol. 2019; 5(12):1749-1768. doi:10.1001/jamaoncol.2019.2996

7. Taplin SH, Dash S, Zeller P [et al.] Oncology: Evidence-Based Approach. New York, NY: Springer Science+Business Media; 2006: 317– 40.

8. Bradley CJ, Yabroff KR, Dahman B. [et al.]. Productivity Costs of Cancer Mortality in the United States: 2000–2020. J Natl Cancer Inst 2008; 100: 1763–1770. DOI: 10.1093/jnci/djn384

9. P. Alison, C. Bradley, P. Hanly [et al.] Projecting productivity losses for cancer-related mortality 2011–2030. BMC Cancer (2016) 16:804. DOI 10.1186/s12885-016-2854-4

10. World Cancer Report. World Health Organization, International Agency for Research on Cancer. Eds.: BW Stewart, P. Kleihues. Lion: IARC Press, 2003; 351.